Sanofi’s Q1 results were ahead of expectations, with growth largely being driven by Dupixent, along with positive contributions from Vaccines and Consumer Healthcare. Still, 2023 guidance was maintained. Overall, we re-iterate our positive stance on Sanofi, drawing comfort from Dupixent’s robust growth prospects, strong position in Vaccines, a healthy balance sheet and expectations of improvement in R&D execution, especially given the recent successes and the change of R&D head. The re-rating th ....
27 Apr 2023
Consensus-beating Q1, guidance unchanged
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Consensus-beating Q1, guidance unchanged
Sanofi’s Q1 results were ahead of expectations, with growth largely being driven by Dupixent, along with positive contributions from Vaccines and Consumer Healthcare. Still, 2023 guidance was maintained. Overall, we re-iterate our positive stance on Sanofi, drawing comfort from Dupixent’s robust growth prospects, strong position in Vaccines, a healthy balance sheet and expectations of improvement in R&D execution, especially given the recent successes and the change of R&D head. The re-rating th ....